NCT07116889 - A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD | Biotech Hunter

Enrollment

156

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

AsthmaCOPD (Chronic Obstructive Pulmonary Disease)

Interventions

BIOLOGICAL

GB-0895 (SC)

Single subcutaneous dose of GB-0895

BIOLOGICAL

GB-0895 (SC)

Multiple subcutaneous doses of GB-0895

DRUG

Placebo (SC)

Single subcutaneous dose of placebo

DRUG

Placebo (SC)

Multiple subcutaneous doses of placebo

Trial Locations (13)

27103

RECRUITING

Southeastern Research Center, Winston-Salem

32720

RECRUITING

Alcanza, DeLand

32808

RECRUITING

Omega Research, Orlando

33173

RECRUITING

Miami Research Institute of South Florida, Miami

55114

ACTIVE_NOT_RECRUITING

Nucleus Network, Saint Paul

77375

RECRUITING

DM Clinical Research, Tomball

Unknown

RECRUITING

Charite Research Organization GmbH, Berlin

RECRUITING

IKF Pneumologie, Frankfurt

RECRUITING

Fraunhofer Institut fur Toxikologie and Experimentelle Medizin (ITEM), Hanover

RECRUITING

Hammersmith Medicines Research, London

RECRUITING

Queen Anne Street Medical Center, London

RECRUITING

Medicines Evaluation Unit (MEU), Manchester

ACTIVE_NOT_RECRUITING

Simbec-Orion Clinical Development, Merthyr Tydfil